HomeCompareYMAB vs SBUX

YMAB vs SBUX: Dividend Comparison 2026

YMAB yields 23.23% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $78.2K in total portfolio value· pulled ahead in Year 9
10 years
YMAB
YMAB
● Live price
23.23%
Share price
$8.61
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$88.8K
Annual income
$9,382.37
Full YMAB calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — YMAB vs SBUX

📍 SBUX pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMABSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMAB + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMAB pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMAB
Annual income on $10K today (after 15% tax)
$1,974.45/yr
After 10yr DRIP, annual income (after tax)
$7,975.01/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $52,490.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMAB + SBUX for your $10,000?

YMAB: 50%SBUX: 50%
100% SBUX50/50100% YMAB
Portfolio after 10yr
$127.9K
Annual income
$40,259.41/yr
Blended yield
31.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

YMAB
Analyst Ratings
8
Buy
6
Hold
2
Sell
Consensus: Buy
Price Target
$12.71
+47.6% upside vs current
Range: $8.60 — $24.00
Altman Z
2.7
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMAB buys
0
SBUX buys
0
No recent congressional trades found for YMAB or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMABSBUX
Forward yield23.23%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$88.8K$167.0K
Annual income after 10y$9,382.37$71,136.45
Total dividends collected$54.4K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$12.71$104.00

Year-by-year: YMAB vs SBUX ($10,000, DRIP)

YearYMAB PortfolioYMAB Income/yrSBUX PortfolioSBUX Income/yrGap
1$13,023$2,322.88$11,121$420.68+$1.9KYMAB
2$16,762$2,827.16$12,548$648.40+$4.2KYMAB
3$21,336$3,400.76$14,440$1,013.98+$6.9KYMAB
4$26,875$4,045.60$17,068$1,617.30+$9.8KYMAB
5$33,519$4,762.52$20,912$2,649.52+$12.6KYMAB
6$41,416$5,551.28$26,875$4,499.29+$14.5KYMAB
7$50,726$6,410.53$36,771$8,014.12+$14.0KYMAB
8$61,614$7,337.86$54,542$15,197.11+$7.1KYMAB
9← crossover$74,257$8,329.89$89,602$31,242.49$15.3KSBUX
10$88,838$9,382.37$167,011$71,136.45$78.2KSBUX

YMAB vs SBUX: Complete Analysis 2026

YMABStock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Full YMAB Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this YMAB vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMAB vs SCHDYMAB vs JEPIYMAB vs OYMAB vs KOYMAB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.